Dennis Schmatz joins Scynexis

Will provide advice to US firm as it advances drug development programme

US drug discovery company Scynexis says Dennis Schmatz has joined the company as a strategic advisor. Schmatz, an anti-infectives specialist, will provide advice to Scynexis’ management team as the company advances its drug development programmes.

Scynexis president and chief executive Dr Yves Ribeill, said: ‘His contributions to Scynexis will be important as we aggressively pursue the development of our cyclophilin inhibitor technology platform and the discovery of global health therapeutics for neglected diseases.’

Schmatz was most recently interim president and chief executive of the Medicines for Malaria Venture, a non-profit foundation in Geneva, Switzerland created to discover anti-malarial drugs through public-private partnerships. Previously he was vice president of Merck Research Laboratories USA and head of the Tsukuba Research Institute of Banyu Research Laboratories in Japan.

‘It's an exciting time to be joining the Scynexis team as both their HCV compounds, SCY-635, and their partnered broad-spectrum antifungal compound, MK-3118, advance through clinical development,’ Schmatz said. ‘I see a promising future for Scynexis and am honoured to be a part of it.’

You may also like

Research & Development

Cypralis to acquire Scynexis assets

The deal includes a large portfolio of cyclophilin inhibitors
Sustainability

Scynexis extends sleeping sickness collaboration to 2012

Extends collaboration with the Drugs for Neglected Diseases initiative (DNDi)
Manufacturing

25 years of Guardtech: Isopod Manufacturing Director Michael Burton Q&A

One of the Group’s longest-serving superstars gives his thoughts on why the Guardtech Group are pushing the boundaries of small-scale cleanroom provision with their rapid-assembly pod systems
Research & Development

Genentech provides update on Astegolimab in chronic obstructive pulmonary disease

Pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every 2 weeks
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Subscribe now